CAJ | 학술논문

目的观察二种不同剂量(10 mg、40 mg)阿托伐他汀治疗急性冠脉综合征(ACS)前后外周血C反应蛋白(CRP)、纤维蛋白原(Fig)、总胆固醇(TC)、低密度脂蛋白胆固醇(LDC-C)的变化、安全性和临床预后的影响.方法 72例ACS患者随机分为大剂量阿托伐他汀(40 mg/d)治疗组(38例)和常规剂量阿托伐他汀(10 mg/d)治疗组(34例),观察2组治疗前及治疗后8周CRP和Fig、TC、LDL-C的水平变化及6个月内主要冠脉不良事件(MACE).结果治疗后大剂量阿托伐他汀治疗组CRP、Fig、TC、LDL-C水平及MACE发生率明显降低,与常规剂量阿托伐他汀治疗组比较有显著意义(P<0.05).结论大剂量阿托伐他汀治疗ACS的疗效优于常规剂量组,同时未增加药物的毒副作用.
목적 관찰이충불동제량(10 mg、40 mg)아탁벌타정치료급성관맥종합정(ACS)전후외주혈C반응단백(CRP)、섬유단백원(Fig)、총담고순(TC)、저밀도지단백담고순(LDC-C)적변화、안전성화림상예후적영향.방법 72례ACS환자수궤분위대제량아탁벌타정(40 mg/d)치료조(38례)화상규제량아탁벌타정(10 mg/d)치료조(34례),관찰2조치료전급치료후8주CRP화Fig、TC、LDL-C적수평변화급6개월내주요관맥불량사건(MACE).결과 치료후대제량아탁벌타정치료조CRP、Fig、TC、LDL-C수평급MACE발생솔명현강저,여상규제량아탁벌타정치료조비교유현저의의(P<0.05).결론 대제량아탁벌타정치료ACS적료효우우상규제량조,동시미증가약물적독부작용.
Objective To investigate the effect and safety and clinic prognosis of two dosage of Atovastatin in treatment of acute coronary Syndrome(ACS)through the change of C-reactive protein(CRP),Fibrinogen(Fig),total cholestrol(TC),LDL-cholestrol(LDL-C)of patients with ACS before and after treatment with two dosage of Atorvastatin.Methods A total of 72 patients with ACS mere randomly assigned into the large dosage of Atorvastatin(40 mg/d)group(n=38)and the routine dosage of Atorvastatin(10 mg/d)before and after 8 weeks treatment and major adverse coronary events(MACE)in six months were observed.Results In the large dosage of Atorvas tatin group,the levels of CRP,Fig,TC,LDL-C and MACE decreased Significantly comparing with the routine dosage of Atorvastatin group(P<0.05).Conclusion The large dosage of Atorvastatin is better than routine dosage of Atorvastatin on treatment for ACS and of good safety.